(Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the ...

(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion, as it looks to diversify its portfolio of experimental drugs with treatments for eye diseases ...

Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall ...

Merck struck a deal to buy Elanco Animal Health’s aqua business in a deal that expands the drugmaker’s animal-health business.

(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported, sending Verve's shares up 84% in ...

Merck & Co. agreed to buy Elanco Animal Health Inc.’s unit that makes farmed fish health products for $1.3 billion.

What Happened: The deal, which could be announced as early as Wednesday, will see Merck pay $1.3 billion in cash upfront to acquire EyeBio, a privately held biotech firm.

Merck said Friday it’s has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion. The drug company MRK will pay an upfront $700 million in cash to ...

Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.

The drugmaker agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments for EyeBio, and will gain access to its retinal disease drug Restoret as part of the deal.

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and the UK, that seeks to treat patients ...